Evidence map›Paper›PMID 41441971›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Prevalence and risk factors of MRONJ in breast cancer patients with CTIBL.

Christian Bacci, Claudia Manera, Francesca Roccuzzo, Mariagrazia Boccuto, Cristina Falci, Stefania Zovato, Sara Watutantrige-Fernando

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Christian BacciOral Pathology and Surgery, Clinical Dentistry, Department of Neurosciences, University of Padova, Padua, Italy. christian.bacci@unipd.it.
Claudia ManeraOral Pathology and Surgery, Clinical Dentistry, Department of Neurosciences, University of Padova, Padua, Italy.
Francesca RoccuzzoOral Pathology and Surgery, Clinical Dentistry, Department of Neurosciences, University of Padova, Padua, Italy.
Mariagrazia BoccutoOral Pathology and Surgery, Clinical Dentistry, Department of Neurosciences, University of Padova, Padua, Italy.
Cristina FalciVeneto Institute of Oncology IOV-IRCCS, Oncology 2, Padua, Italy.
Stefania ZovatoCancer Family Clinic, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Sara Watutantrige-FernandoCancer Family Clinic, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with hormone-receptor positive breast cancer (BC) often receive Adjuvant Endocrine Therapy (AET), which can cause Cancer Treatment-Induced Bone Loss (CTIBL). To prevent CTIBL, low-dose Bone-Modifying Agents such as bisphosphonates and Denosumab are prescribed. Although effective, these drugs can cause Medication-Related OsteoNecrosis of the Jaw, a rare but severe adverse event. The prevalence of MRONJ in this patient population is still unclear.

objectivesThis study aims to estimate the prevalence of MRONJ in female patients with hormone-responsive BC on AET who are treated with low-dose BMAs to prevent CTIBL, evaluate the effectiveness of preventive dental visits in reducing MRONJ risk, and stratify the risk of MRONJ onset based on systemic and local risk factors. MATERIALS AND

methodsA retrospective longitudinal cohort study of 200 patients was conducted at two centers in Italy. Medical history, clinical, and radiographic data were collected from medical records. Patients with MRONJ were evaluated for clinical signs, radiographic findings, intraoral risk factors, and staging according to SIPMO-SICMF (Italian Society of Oral Pathology and Medicine and Italian Society of Maxillofacial Surgery) and AAOMS (American Association of Oral And Maxillofacial Surgeons) criteria.

resultsThe MRONJ event occurred in 9/200 patients (4.5%); 44.5% of patients with MRONJ had received a preventive dental visit. The most frequent local risk factors were plaque and tartar (88.5%), root remnants (44.5%), and severe periodontitis (22.5%).

conclusionsThe prevalence of MRONJ in females treated with low-dose BMAs is higher than reported in the literature. Moreover, in this female cohort, MRONJ risk seems to be higher than that of osteoporotic patients treated with low-dose BMAs and lower than in metastatic cancer patients treated with high-dose BMAs. Preventive dental visits seem to reduce the risk and severity of MRONJ. Various systemic and local risk factors contribute to the onset of MRONJ in this emerging population.

Indexed as

Antineoplastic Agents, HormonalBisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsBreast NeoplasmsAdultAgedAged, 80 and overCohort StudiesDenosumabDiphosphonatesFemaleHumansItalyLongitudinal StudiesMiddle AgedPrevalenceAntineoplastic Agents, HormonalBone Density Conservation AgentsDenosumabDiphosphonatesBreast cancerBRONJCancer treatment-induced bone lossCTIBILMedication-Related OsteoNecrosis of the JawMRONJONJ

Identifiers

PMID41441971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.